FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileChimeric Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CHM.AX
Chimeric Therapeutics Limited Stock AnalysisComprehensive stock analysis for Chimeric Therapeutics Limited (CHM.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCHM.AX
CHM.AX
Chimeric Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CHM.AX
  1. Home
  2. Stocks
  3. Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

🇦🇺CHM.AX•ASX

Chimeric Therapeutics Limited

🇦🇺CHM.AX•ASX

Your view on CHM.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Chimeric Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Rebecca McQualter
Headquarters
62 Lygon Street, Carlton, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Rebecca McQualter
Headquarters
62 Lygon Street, Carlton, VIC, AU
Description

Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers.

Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+.

Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors.

The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Chimeric Therapeutics Limited. Starting points for Chimeric Therapeutics Limited: EPS -AUD 1.50, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Chimeric Therapeutics Limited. Chimeric Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Chimeric Therapeutics Limited. Trailing twelve-month EPS for Chimeric Therapeutics Limited stands at -AUD 1.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent YearFY Jun 2027
Avg. estimateAUD 0.00
Low estimateAUD 0.00
High estimateAUD 0.00
No. of analysts0
Year-ago EPS−AUD 0.61
Growth+100.0%

Revenue Estimate

RevenueCurrent YearFY Jun 2027
Avg. estimateAUD 480.58M
Low estimateAUD 480.58M
High estimateAUD 480.58M
No. of analysts1
Year-ago revenueAUD 0.00
Growth—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Chimeric Therapeutics Limited. Chimeric Therapeutics Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CHM.AX20 companies
Compare CHM.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
1AD.AXAdAlta LimitedHealthcareBiotechnology—
ACR.AXAcrux LimitedHealthcareBiotechnology—
BGT.AXBio-Gene Technology LimitedBasic MaterialsAgricultural Inputs—
BIT.AXBiotron LimitedHealthcareBiotechnology—
CAN.AXCann Group LimitedHealthcareDrug Manufacturers - Specialty & Generic—
ECS.AXECS Botanics Holdings LtdHealthcareDrug Manufacturers - Specialty & Generic—
HIQ.AXHITIQ LimitedHealthcareMedical - Healthcare Information Services—
IXC.AXInvex Therapeutics LtdHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PHYOFIXICO plcHealthcareOTC$6.5M
PKTXProtoKinetix, IncorporatedHealthcareOTC$2.7M
PLRXPliant Therapeutics, Inc.HealthcareNASDAQ$41.0M
PLRZPolyrizon Ltd.HealthcareNASDAQ$12.4M
PLURPluri Inc.HealthcareNASDAQ$9.9M
PLXProtalix BioTherapeutics, Inc.HealthcareAMEX$254.6M
PLYXPolaryx Therapeutics, Inc. Common StockHealthcareNASDAQ$80.3M
PMCBPharmaCyte Biotech, Inc.HealthcareNASDAQ$3.0M
PMNProMIS Neurosciences, Inc.HealthcareNASDAQ$28.2M
PMVPPMV Pharmaceuticals, Inc.HealthcareNASDAQ$65.1M
POLBFPoolbeg Pharma PLCHealthcareOTC$46.6M
PPBTPurple Biotech Ltd.HealthcareNASDAQ$236,124
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Chimeric Therapeutics Limited. Coverage tracks Chimeric Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Chimeric Therapeutics Limited.

CHM.AX AnalysisWeak
Past
1
Growth
1
Health
1
Profit
1
Value
1

News

Latest Market News